Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy

Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Shih-Hsing, Liu, Yi-Ching, Dai, Zen-Kong, Chen, I-Chen, Wu, Yen-Hsien, Hsu, Jong-Hau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959725/
https://www.ncbi.nlm.nih.gov/pubmed/33732669
http://dx.doi.org/10.3389/fped.2021.639551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959725/
https://www.ncbi.nlm.nih.gov/pubmed/33732669
http://dx.doi.org/10.3389/fped.2021.639551

Ejemplares similares